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Evaluating the ability of economic models of diabetes to simulate new cardiovascular 
outcomes trials: a report on the Ninth Mount Hood Diabetes Challenge 
Abstract 
Objectives: The cardiovascular outcomes challenge examined the predictive accuracy of 10 
diabetes models in estimating hard outcomes in two recent cardiovascular outcomes trials 
(CVOTs) and whether recalibration can be used to improve replication. 
Methods: Participating groups were asked to reproduce the results of the Empagliflozin 
Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG 
OUTCOME) and the Canagliflozin Cardiovascular Assessment Study (CANVAS) Program. 
Calibration was performed and additional analyses assessed model ability to replicate 
absolute event rates, hazard ratios (HRs), and the generalizability of calibration across 
CVOTs within a drug class. 
Results: Ten groups submitted results. Models underestimated treatment effects (i.e., HRs) 
using uncalibrated models for both trials.  Calibration to the placebo arm of EMPA-REG 
OUTCOME greatly improved the prediction of event rates in the placebo, but less so in the 
active comparator arm.  Calibrating to both arms of EMPA-REG OUTCOME individually 
enabled replication of the observed outcomes.  Using EMPA-REG OUTCOME-calibrated 
models to predict CANVAS Program outcomes was an improvement over uncalibrated 
models but failed to capture treatment effects adequately.  Applying canagliflozin HRs 
directly provided the best fit.  
Conclusions: The Ninth Mount Hood Diabetes Challenge demonstrated that commonly used 
risk equations were generally unable to capture recent CVOT treatment effects but that 
calibration of the risk equations can improve predictive accuracy.  While calibration serves as 




extrapolate generally to other settings, time horizons, and comparators. New methods and/or 
new risk equations for capturing these CV benefits are needed.  
 
Highlights 
• Diabetes health economic models are commonly developed based on risk equations 
using classic risk factors such as glycated hemoglobin, systolic blood pressure, lipid 
level, and body mass index. However, existing models might not account for the entire 
cardioprotective effects of new treatments observed in recent cardiovascular outcomes 
trials (CVOTs). 
• This paper shows that existing risk factor-based health economics models in diabetes 
have limitations in predicting the results of CVOTs. Calibration of these risk functions 
to the observed data only partially resolves these issues. 
• Future models may require new methods and/or new risk equations that promote 








Use of economic modelling is widespread and necessary (1, 2), particularly for chronic and 
progressive diseases like diabetes mellitus (DM) for which the decision-maker’s time horizon 
(often lifetime) is longer than clinical trial durations.  Health economic modelling provides a 
unique tool that combines the best available epidemiological data for disease progression and 
health outcomes with trial (often relatively short-term) data and enables the extrapolation of 
the health and cost consequences of health interventions over long time horizons.  Economic 
modelling, moreover, facilitates economic evaluation between competing treatment 
interventions in the absence of head-to-head data.   
Economic modelling has a long history of use in type 2 DM (T2DM). Modelling T2DM is 
challenging, as it affects multiple inter-related organ systems, and complications occur over 
long-time horizons during which event rates tend to increase. Comorbid conditions such as 
hypertension, dyslipidaemia, and obesity are common, and treatments for diabetes and 
comorbid conditions frequently work on the same set of biomarker risk factors and require 
intensification over time (3).  Given the expense and intellectual capital required to construct 
health economic models of DM, most have been developed with the goal of supporting 
multiple applications covering different settings and comparisons.   
Historically, economic modelling of T2DM treatment interventions has featured projection of 
differences in these biomarker risk factors into economically relevant outcomes (e.g., event 
rates, life expectancy, quality-adjusted life years and costs) over long time horizons using risk 
prediction equations. Risk prediction equations, by design, reflect treatment conditions 
prevailing during the follow-up period of the underlying data, which may not match current 
standards of care. The widely used United Kingdom Prospective Diabetes Study (UKPDS) 




a wide range of contemporary cohorts (6-10).  Given that important risk equations are 
inevitably backward-looking, as they require outcomes over long time horizons and practice 
standards change over this time, calibration  has been proposed as a way to improve the 
predictive accuracy of valuable risk equations (11, 12).  When conducted transparently, 
calibrated and appropriately validated, health economic modelling can be a valuable decision-
making aid.   
In 2015, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus 
Patients (EMPA-REG OUTCOME) (13) found that the sodium-glucose co-transporter-2 
(SGLT2) inhibitor empagliflozin was not only safe but that it had significantly lower rates of 
the primary composite outcome of death from cardiovascular causes, nonfatal myocardial 
infarction, or nonfatal stroke versus placebo. Since then, five more cardiovascular outcomes 
trials (CVOTs) in patients with established CV disease or greatly increased CV risk have 
reported cardioprotective effects for SGLT-2-inhibitors and glucagon-like peptide-1 (GLP-1) 
receptor agonists: the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular 
Outcome Results (LEADER) (14), Trial to Evaluate Cardiovascular and Other Long-term 
Outcomes with Semaglutide in Subjects with Type 2 Diabetes (SUSTAIN-6) (15), the 
Canagliflozin Cardiovascular Assessment Study (CANVAS Program) (16), Dapagliflozin 
Effect on CardiovascuLAR Events (DECLARE-TIMI 58) (17) and the Albiglutide and 
Cardiovascular Outcomes in Patients with Type 2 Diabetes and Cardiovascular Disease 
(Harmony Outcomes) (18). These cardioprotective effects reported cannot be fully explained 
by improvements in known biomarker risk factors (19). Applications with three independent 
diabetes simulation models have failed to replicate these treatment effects based on changes in 
surrogate biomarkers for most CV outcomes (20-22), highlighting an important challenge for 




Initiated in 2000 by Andrew Palmer and Jonathan Brown at Timberline Lodge, Mount Hood, 
Oregon, USA (23), the Mount Hood Diabetes Challenge is a biennial congress in which 
diabetes modelling groups have met to compare and contrast models, methods, and data in the 
context of simulating standardized treatment scenarios and discussing the results. So far, eight 
Mount Hood Diabetes Challenge meetings have been held, with the aims of improving 
performance (24, 25) and input transparency (26) of diabetes models.  In light of the evidence 
that cardioprotective benefit from newer diabetes medications such as GLP-1 receptor 
agonists and SGLT2-inhibitors cannot be fully explained by traditional physiological 
biomarkers such as glycated haemoglobin (HbA1c), systolic blood pressure (SBP) and body 
mass index (BMI), the Ninth Mount Hood Diabetes Challenge was convened with, in part, the 
aims of: 
1.  examining the predictive accuracy of diabetes models on hard endpoints in two recent 
CVOTs and 
2. examining whether recalibration can be used to better replicate CVOT results. 
 
Methods 
The Ninth Mount Hood Diabetes Challenge was advertised on the Mount Hood Diabetes 
Challenge web site (https://www.mthooddiabeteschallenge.com/) and was open to all 
interested health economic modelling groups.  Diabetes modelling groups registered within 
Mount Hood Diabetes Challenge Network were also informed directly via email.   
The scope and parameters of the challenge were proposed by the modelling groups and 
debated, and the final conference program featured three challenge exercises (instructions 
were provided, and results were expected to be sent back prior to the conference). The first 




Quality of Life Challenge and a Diabetes versus Non-Diabetes Simulation Models Challenge.  
The details of each challenge can be found on the Mount Hood Diabetes Challenge web site.  
The focus of this article is limited to the CV Outcomes Challenge (Day 1), which aimed to 
evaluate how well existing diabetes simulation models replicated the absolute event rates and 
treatment effects observed for key endpoints in recent CVOTs, in particular EMPA-REG 
OUTCOME trial (13, 27) and the CANVAS Program (16, 28)  A standard set of instructions 
(Supplementary Appendix 1) was provided to participating modelling groups in each 
challenge exercise and is summarised below.   
EMPA-REG OUTCOME Challenge  
The groups were asked to replicate the EMPA-REG OUTCOME trial (13, 27), separately by 
empagliflozin (pooling 10 mg and 25 mg doses) and placebo arms, by loading their models 
with weighted average baseline patient characteristics and treatment effects on key 
biomarkers over 3 years and then simulating for a period of 3 years (trial mean follow-up was 
3.0 years for the treatment group).  Modelling groups were asked to use the data provided in 
the instructions or in the study publications listed in the instructions to the extent possible.  
The groups were asked to document any deviations from the instructions (e.g., additional 
assumptions or covariates required for the model to run the simulations) and submit them with 
the results. Three scenarios were simulated: 
Scenario A: Each modelling group simulated EMPA-REG OUTCOME using their model 
without modifications (i.e., without calibration). 
Scenario B: Each modelling group was instructed to calibrate their model to the results of the 
placebo arm in EMPA-REG OUTCOME, using calibration techniques appropriate for their 
model construction and documenting the methodology used. The models re-simulated EMPA-




Scenario C: Each modelling group calibrated their model to the results of the empagliflozin 
arm in EMPA-REG OUTCOME. These new calibration factors were used to re-simulate the 
empagliflozin arm only (the results for the placebo arm were recycled from Scenario B).  
CANVAS Program Challenge  
To evaluate the ability of models calibrated to one CVOT (in this case, EMPA-REG 
OUTCOME) to duplicate the results of another CVOT (16, 28), that is generalizability, the 
modelling groups were asked to replicate the CANVAS Program trial as well (but using the 
EMPA-REG OUTCOME calibration factors).  The models were loaded with baseline patient 
characteristics and treatment effects on key biomarkers and then simulated for 4 years (mean 
follow-up in the CANVAS Program was 3.6 years), separately for the placebo and 
canagliflozin study arms.  Modelling groups were asked to use the data provided in the 
instructions or in the study publications listed in the instructions to the extent possible.  The 
groups were asked to document any deviations from the instructions (e.g., additional 
assumptions or covariates required for the model to run the simulations) and submit them with 
the results. Four scenarios were simulated: 
Scenario A: Each modelling group simulated their model without modification (i.e., without 
calibration). 
Scenario B: Each modelling group was instructed to re-run their model with the calibration 
factors that were estimated using the placebo arm in EMPA-REG OUTCOME (i.e., 
calibration factors from EMPA-REG OUTCOME Challenge Scenario B above). The models 
were re-run using the same calibration factors for both canagliflozin and placebo arms. 
Scenario C: To evaluate how well cardioprotection can be captured when the trial observed 
hazard ratios (HRs) are entered as inputs into the model, each modelling group was instructed 




model together with the observed HRs for canagliflozin versus placebo published for the 
CANVAS Program. The models were re-run for the canagliflozin arm and the results for the 
placebo arm were recycled from Scenario B. 
Scenario D: To evaluate how well calibration to the study arms in EMPA-REG OUTCOME 
individually captures cardioprotection in the CANVAS Program, each modelling group was 
instructed to simulate the canagliflozin arm using the calibration factors obtained in the 
EMPA-REG OUTCOME Challenge Scenario C (and without using direct HR inputs for 
canagliflozin). The models were re-run for the canagliflozin arm and the results for the 
placebo arm were recycled from Scenario B. 
Results were presented and discussed by representatives from the modelling groups and other 
interested stakeholders. A recurring theme in the discussion was how to address the 
limitations of existing modelling approaches for considering cardioprotection, and paths to 
methodological improvement were debated. Representatives from each of the modelling 
groups were invited to participate in the development of meeting proceedings articles.  
Modelling groups were also contacted after the meeting to confirm their final submitted 
results, where correction of typographical errors was permitted but re-simulation was not. 
Reporting of challenge results  
A standard reporting format was provided to participating groups (29). Modelling groups 
were encouraged to submit results for each challenge. Groups were asked to document all 
their assumptions made in the challenge.  Modelling groups were requested to report both 
cumulative incidence and event rates across 15 outcomes including death from any cause, 
death from CV cause, nonfatal myocardial infarction (MI), nonfatal or fatal MI, nonfatal 
stroke, nonfatal or fatal stroke, hospitalization for heart failure (HHF), hospitalization for 




cardiovascular events (MACE), coronary revascularization procedure, transient ischaemic 
attack (TIA) and amputations.  Because few of the modelling groups submitted results for 
micro- and macroalbuminuria and it was unclear whether the results reflected new onset or 
overall prevalence, renal outcomes were excluded from analysis.  In addition, for the sake of 
brevity, goodness-of-fit was reported only for event rates and for key macrovascular 
outcomes, namely CV death, nonfatal or fatal MI, nonfatal or fatal stroke, HHF and MACE. 
All data submitted by the modelling groups, however, are presented in Supplementary 
Appendix 2. 
Mean absolute event rates for each outcome were computed separately by study arm based on 
individual rates submitted by the modelling groups. Treatment effects were calculated as HRs 
based on mean HRs reported by the modelling groups (using Microsoft Excel®). Concordance 
between the mean model predictions and the results of the CVOTs was measured using mean 
of absolute percentage errors (MAPEs) calculated by the modelling groups (30).  Box and 
whisker plots were used to summarize the distribution of event rates for each of these 
endpoints, separately for each scenario using the ggplot2 package in R Project (31, 32).  
 
Results 
On October 6-7, 2018, 15 modelling groups gathered at the German Diabetes Center in 
Düsseldorf, Germany. Ten modelling groups participated in the CV Outcomes Challenge: 
BRAVO of diabetes model, Cardiff Model, CDC/RTI model, IQVIA-CDM, the Economic 
and Health Outcomes Model of Type 2 DM (ECHO-T2DM), Michigan Model for Diabetes 
(MMD), PROSIT diabetes modelling community, SPHR Type 2 Diabetes Treatment model, 
The Treatment Transition Model (TTM,) and UKPDS-OM2. The Cardiff Model submitted 




Short biographies of participating models in the CV Outcome Challenge can be found in 
Supplementary Appendix 3. Not all groups submitted results for every endpoint and scenario. 
The outcomes reported by each modelling group are summarized in Table 1. Results for the 
full set of outcomes are presented in Supplementary Appendix 4. 
<Table 1 should be inserted here> 
EMPA-REG OUTCOME Challenge 
The results for the EMPA-REG OUTCOME Challenge are presented in Table 2 and in Figure 
1. Table 2 summarizes mean predicted event rates (by study arm), HRs and MAPE for key 
macrovascular outcomes (CV death, MI, stroke, HHF and MACE), together with the results 
observed in EMPA-REG OUTCOME. Panel A includes the uncalibrated set of results 
(Scenario A in the EMPA-REG OUTCOME challenge), Panel B the placebo-calibrated 
results (Scenario B in the EMPA-REG OUTCOME challenge), and Panel C the 
empagliflozin- and placebo-calibrated results (Scenario C in the EMPA-REG OUTCOME 
challenge).   
<Table 2 should be inserted here> 
<Figure 1 should be inserted here> 
In the uncalibrated scenario (Panel A), MAPE for event rates of all outcomes combined for 
the treatment arm and placebo arm were 57.8% and 46.5% respectively.  Of note, none of the 
modelling groups reproduced the increased but statistically nonsignificant increased risk for 
stroke that was observed in the EMPA-REG OUTCOME trial. In addition, treatment effects 
were generally underestimated, with MAPE ranging from 11.6% for the MI outcome to 
55.0% for CV death (27.7% for all outcomes combined). The mean uncalibrated predictions 




largest for MACE. The EMPA-REG OUTCOME observed values fell within the interquartile 
ranges of the predicted results for 3 of the 5 endpoints for both study arms. 
In the placebo-calibrated scenario (Panel B), MAPE for event rates overall and individually 
for the placebo arm was much improved when compared to Scenario A. The mean predicted 
event rate for the empagliflozin arm was also improved, but not to the same degree. 
Consistent with the improvement in MAPE for event rates in the placebo group, MAPE for 
HRs were also reduced. However, there was still a 23.7% MAPE between predicted and 
observed values for all outcomes after calibrating to the placebo group.  
In the empagliflozin- and placebo-calibrated scenario (Panel C), MAPE for HRs was further 
reduced compared with the placebo-calibrated scenario as the result of the improvement in 
calibrating event rates in the treatment arm.  The modelling groups were able on average to 
replicate the increased risk of stroke in the empagliflozin arm closely. All MAPEs for HR fell 
below 5% after calibration applied to both treatment and placebo groups.     
CANVAS Program Challenge 
The results for the CANVAS Program challenge are presented in Table 3 and Figure 2. Table 
3 summarizes the mean predicted event rates by study arm and HRs for CV death, MI, stroke, 
HHF and MACE, together with the observed values and MAPE. Panel A includes the 
uncalibrated set of results (Scenario A in the CANVAS Program challenge), Panel B the 
placebo-calibrated results (Scenario B in the CANVAS Program challenge), Panel C the 
placebo-calibrated with CANVAS Program HR results (Scenario C in the CANVAS Program 
challenge), and Panel D the empagliflozin- and placebo-calibrated results (Scenario D in the 
CANVAS Program challenge). 
<Table 3 should be inserted here> 




In the uncalibrated scenario (Panel A), modelling groups tended to overestimate event rates of 
macrovascular outcomes in both treatment and placebo arms. In addition, treatment effects 
predicted by modelling groups tended to be smaller than observed in the CANVAS Program. 
MAPEs of HRs were generally smaller compared to MAPE in the EMPA-REG OUTCOME 
challenge, even though the MAPE of HR for HHF remained high as modelling groups 
generally estimated little or no benefit in contrast to an observed 33% reduction in HHF in the 
CANVAS Program. Moreover, the CANVAS Program observed values fell within the 
interquartile ranges of the predicted results for all but one prediction (Figure 2). 
In the placebo-calibrated scenario (Panel B), where models were calibrated to the event rates 
observed in the placebo arm of EMPA-REG OUTCOME trial, MAPEs for event rates in the 
placebo arm decreased for CV death, stroke, and MACE but increased for MI and HHF 
compared to scenario A.  Not surprisingly, prediction of treatment effect did not improve 
compared to scenario A.  
In the placebo-calibrated plus canagliflozin HRs scenario (Panel C), where the same 
calibration to the EMPA-REG OUTCOME placebo arm was combined with direct input of 
CANVAS Program observed HRs, mean predicted macrovascular event rates for the 
canagliflozin arm tended to improve compared to scenario A, except for MI and HHF. 
Notably, the predicted event rates for CV death and stroke were almost identical to those 
observed in the CANVAS Program.  The MAPE of treatment effect for all outcomes in 
scenario C decreased to 8.7% from 23.0% in scenario A.  
In the empagliflozin- and placebo-calibrated scenario (Panel D), MAPE for macrovascular 
event rates in the treatment arm were similar or larger (substantially so for stroke) than those 




treatment effects for each macrovascular outcome further diverged from that in scenario C, 
HRs that exceeded 1.0 for stroke and HHF.  
 
Discussion 
This article summarizes the findings of the CV Outcomes Challenge in the Ninth Mount Hood 
Diabetes Challenge. Models tended to underestimate treatment effects using their existing risk 
prediction equations based on traditional biomarkers such as HbA1c, SBP and BMI. In the 
EMPA-REG OUTCOME challenge where calibration was conducted only using evidence 
from EMPA-REG OUTCOME trial, calibration considerably improved predictions and 
generally enabled the replication of outcomes that were observed in the EMPA-REG 
OUTCOME trial.  In the CANVAS Program challenge, where calibration was conducted 
using evidence both from the EMPA-REG OUTCOME and CANVAS Program trials, 
calibration performed better using HRs from the CANVAS Program trial directly rather than 
relying on EMPA-REG OUTCOME calibration.   
The design of these and other recent CVOTs reflects the guidance issued by the US Food and 
Drug Administration in December 2008, which responded to previous safety concerns by 
mandating long-term CVOTs for safety as a prerequisite to obtaining approval for 
antidiabetes drugs in type 2 diabetes (33). The resulting trials tend to have large sample sizes 
and long study durations, aim to maintain “glycaemic equipoise” rather than a glucose-
lowering trial design, and measure hard outcomes like MACE directly (19). While CVOT 
durations are longer than most short-term glucose lowering trials, extrapolation using risk 
prediction equations is still required to fully capture the long-term costs and benefits (3).  
Adequately capturing all CV effects in CVOTs with current economic modelling methods 




receptor agonists, have reported treatment effects that cannot be explained only by 
improvements in known biomarker risk factors, and hence models including these risk factors 
in their risk predictions cannot be expected to fully capture the reported outcomes, at least 
until the mechanisms of action are better understood (20-22). The Ninth Mount Hood 
Diabetes Challenge has confirmed this finding. Second, widely used risk equations such as 
the UKPDS 68 and the UKPDS 82 reflect cohorts initially recruited in an earlier “therapeutic 
era”, since when improved clinical care and many other factors have contributed to secular 
declines in morbidity and mortality in type 2 diabetes and in cardiovascular disease generally 
(34). The UKPDS study participants were also newly diagnosed with diabetes at recruitment 
(35), whereas recent CVOTs have typically recruited patients with long diabetes duration and 
established (sometimes quite severe) cardiovascular disease, although it should be noted that 
the UKPDS-OM2 was estimated using patient data with a median of 17.6 years follow up, 
during which many complications occurred.  Third, the glycaemic equipoise design may 
encourage the adoption of more intensive and often multi-therapy treatment in patients in the 
placebo arm to reach similar biomarker values across study arms.  This would be captured in 
a trial-based economic analysis as additional treatment costs in the comparator arm, and may 
not be unrealistic insofar as treating to target plays an increasing role in many standard 
treatment guidelines. There is also substantial heterogeneity within and across CVOTs, 
importantly including baseline patient characteristics such as the presence or absence of prior 
cardiovascular disease (13, 16). Although reported in aggregate results, such heterogeneity 
may be hard to model without access to individual patient data.  Lastly, CVOTs are placebo-
controlled, so to inform policy, evidence of differences with active comparators must be 
established indirectly, which requires knowledge of their impact on biomarkers and 




Considering the above challenges, diabetes health economics modellers, are encouraged to 
adapt their methods and risk equations to reflect the cardioprotection observed in CVOTs. 
Calibration to individual trials is not a panacea, however, and some key limitations of the 
approach must be acknowledged. First, the successful replication in the EMPA-REG 
OUTCOME Challenge were limited to the short time horizon of the trial and it does not shed 
light on how well it applies to the longer time horizons that are often required in the economic 
modelling of DM.  Nor did the exercise shed light on the robustness of extrapolation to 
different treatment settings, a frequent goal of health economic modelling. Second, the 
CANVAS Program Challenge demonstrated unsurprisingly that the calibrations from one 
CVOT extrapolate poorly to another CVOT.  The differential features of the CVOTs, thus, 
dictate careful consideration and individual tailoring (and perhaps even separate models) to 
adequately model the cardioprotective effect observed in the CVOTs, though with careful 
documentation and explanation to ensure stakeholder face validity. Third, when the goal is to 
compare the results of two or more CVOTs (and not merely compare an active agent versus 
the placebo arm within a CVOT), it is unclear that calibrating to the separate trials 
individually would be viewed as credible.  Moreover, comparisons of interventions using data 
from separate trials may be required and it remains unclear how calibration may be performed 
given substantial trial heterogeneity and a limited number of CVOTs. Alternative approaches 
that are straightforward and practical for predicting outcomes of CVOTs should therefore be 
explored. Two approaches may reward further exploration. First, it may be possible to modify 
existing models so that the effects of observed risk factor change on outcomes continue to be 
simulated, but in addition the residual “unexplained” treatment effects on outcomes are 
modelled directly as changes in the outcome probabilities for treated patients. Second, 
modellers need to closely follow and ideally participate in efforts to better understand 




novel biomarkers being identified that could then be incorporated in future risk equations and 
models.  
The CV Outcomes Challenge itself also had several limitations. First, it was impossible to 
provide instructions in sufficient detail to ensure that all modelling groups would apply 
exactly the same methods, given that model structures are so different, so some divergence in 
implementation was inevitable. Calibration methods in particular were left to each modelling 
group’s discretion, which may flavour the results (the methods used by each model are 
reported in Supplementary Appendix 5). Moreover, most modelling groups generally limited 
calibration to the subset of endpoints in their models that were informed by risk prediction 
equations directly (e.g., models based on UKPDS Outcomes Model generally include all MI, 
but some of the models reported nonfatal MI as well), which can be observed in the modest, 
but non-zero MAPE values in Panel C of the EMPA-REG OUTCOME Challenge. Second, 
not all model groups participated in all parts of the challenge, which complicates comparison 
across scenarios. Third, some of the CVOT outcome definitions may differ from the 
corresponding outcomes in some of the models. For example, HHF in the CVOTs may match 
poorly to HF in models that use the UKPDS Outcomes Model.  
 
Conclusions 
The Ninth Mount Hood Diabetes Challenge provides evidence that existing risk factor-driven 
diabetes models have limitations when estimating the entire treatment effects observed in 
recent CVOTs. While calibration to the current diabetes models serves as a practical approach 
to improve the accuracy of predicting the reported CVOTs outcomes, it has several limitations 
regarding extrapolation to new settings and longer time horizons. Non-placebo comparisons 




factor/treatment effect modelling, and the exploration of new biomarkers for newer drug 
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ACM X X X X X X X X X X X 
CV Death X X X X X X X X -- X X 
Nonfatal MI X X -- -- X -- X X -- X -- 
Nonfatal or Fatal MI X X X X X X X X X X X 
Nonfatal Stroke X X -- -- X -- X X -- X -- 
Nonfatal or Fatal Stroke X X X X X X X X X X X 
HHF X X X -- X X X -- X X X 
HA X -- -- X -- X -- -- X X X 
MACE X -- -- -- X -- X X -- X -- 
Coronary Revascularization  X -- -- -- -- -- X -- -- -- -- 
TIA -- -- -- -- -- -- -- -- -- -- -- 
Amputation -- X X -- X X -- X X X X 
ACM, all-cause mortality; CV, cardiovascular; MI, myocardial infarction; HHF, hospitalization for heart failure; HA, hospitalization for angina; MACE, major adverse 













Predicted MAPE (%) 
EMPA-REG 
OUTCOME 
Predicted MAPE (%) 
EMPA-REG 
OUTCOME 
Predicted MAPE (%) 
A. Uncalibrated                 
CV Death 10 12.4 19.0 57.9 20.2 19.5 33.7 0.62 0.96 55.0 
MI 11 16.8 17.1 21.1 19.3 17.8 19.4 0.87 0.97 11.6 
Stroke 11 12.3 8.3 48.2 10.5 9.1 42.0 1.18 0.91 23.3 
HHF 9 9.4 6.8 31.1 14.5 7.5 48.5 0.65 0.92 41.4 
MACE 5 37.4 37.9 47.6 43.9 39.7 43.8 0.86 1.11 30.5 
All Outcomes*  85 NA NA 57.8 NA NA 46.5 NA NA 27.7 
B. PBO-Calibrated                 
CV Death 7 12.4 14.5 32.4 20.2 18.1 11.2 0.62 0.81 40.9 
MI 7 16.8 18.2 8.4 19.3 19.3 4.3 0.87 0.94 8.4 
Stroke 7 12.3 9.7 21.3 10.5 10.7 2.7 1.18 0.90 23.3 
HHF 6 9.4 12.6 33.5 14.5 13.9 4.0 0.65 0.90 39.1 
MACE 3 37.4 37.7 14.9 43.9 40.2 12.0 0.86 0.94 10.4 
All Outcomes* 55 NA NA 27.1 NA NA 10.1 NA NA 23.7 
C. Empagliflozin-& 
PBO-Calibrated 
                
CV Death 7 12.4 11.3 11.0 20.2 18.1 11.2 0.62 0.62 1.8 
MI 7 16.8 16.6 2.2 19.3 19.3 4.3 0.87 0.86 2.0 
Stroke 7 12.3 12.5 3.8 10.5 10.7 2.7 1.18 1.17 4.9 
HHF 6 9.4 9.4 2.6 14.5 13.9 4.0 0.65 0.68 4.4 
MACE 3 37.4 35.1 9.1 43.9 40.2 12.0 0.86 0.88 4.4 
All Outcomes* 55 NA NA 9.2 NA NA 10.1 NA NA 4.1 
NA, not applicable; EMPA-REG OUTCOME, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients; CV, 
cardiovascular; MI, myocardial infarction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular event. 














Predicted MAPE (%) 
CANVAS 
Program 
Predicted MAPE (%) 
CANVAS 
Program 
Predicted MAPE (%) 
A. Uncalibrated              
CV Death 9 11.6 14.3 51.5 12.8 15.0 46.0 0.87 0.96 12.6 
MI 10 11.2 15.2 53.8 12.6 16.0 49.1 0.89 0.98 10.7 
Stroke 10 7.9 8.0 44.9 9.6 8.7 41.4 0.87 0.92 11.4 
HHF 8 5.5 6.1 24.5 8.7 6.3 31.5 0.67 0.99 47.1 
MACE 4 26.9 32.6 72.8 31.5 34.2 66.7 0.86 1.01 17.7 
All Outcomes* 71 NA NA 64.4 NA NA 80.1 NA NA 23.0 
B. Placebo-calibrated                
CV Death 7 11.6 13.1 35.5 12.8 14.5 30.3 0.87 0.90 9.5 
MI 7 11.2 19.0 77.5 12.6 20.9 66.2 0.89 0.89 8.6 
Stroke 7 7.9 8.5 25.9 9.6 9.9 15.6 0.87 0.86 12.3 
HHF 6 5.5 14.6 165.9 8.7 14.4 85.2 0.67 1.28 91.4 
MACE 3 26.9 35.5 36.4 31.5 37.8 31.3 0.86 0.94 9.3 
All Outcomes* 51 NA NA 61.2 NA NA 48.4 NA NA 24.8 
C. Placebo-calibrated & 
canagliflozin HRs 
               
CV Death 7 11.6 11.4 21.8 12.8 14.5 30.3 0.87 0.78 10.2 
MI 7 11.2 17.3 55.4 12.6 20.9 66.2 0.89 0.83 6.3 
Stroke 7 7.9 7.9 14.1 9.6 9.9 15.6 0.87 0.80 9.1 
HHF 6 5.5 9.1 85.1 8.7 14.4 85.2 0.67 0.63 6.8 
MACE 3 26.9 30.9 28.6 31.5 37.8 31.3 0.86 0.82 5.9 
All Outcomes* 51 NA NA 41.4 NA NA 48.4 NA NA 8.7 
D. Empagliflozin-& placebo-
calibrated 
               
CV Death 7 11.6 8.8 24.2 12.8 14.5 30.3 0.87 0.61 29.8 
MI 7 11.2 16.9 59.1 12.6 20.9 66.2 0.89 0.81 9.4 
Stroke 7 7.9 10.6 44.0 9.6 9.9 15.6 0.87 1.08 32.7 
HHF 6 5.5 10.9 99.0 8.7 14.4 85.2 0.67 1.07 65.4 
MACE 3 26.9 32.4 27.6 31.5 37.8 31.3 0.86 0.87 5.6 
All Outcomes* 51 NA NA 47.4 NA NA 48.4 NA NA 31.7 
NA, not applicable; CANVAS, the Canagliflozin Cardiovascular Assessment Study; CV, cardiovascular; MI, myocardial infarction; HHF, hospitalization for heart failure; MACE, 
major adverse cardiovascular event. 




Figure 1: Box-and-Whisker Plots of predicted event rates (per 1000 patient-years) for key 
macrovascular outcomes, by scenario and arm in the EMPA-REG OUTCOME Challenge. Event 
rates observed in EMPA-REG OUTCOME are depicted by stars.  
EMPA-REG OUTCOME, the Empagliflozin Cardiovascular Outcome Event Trial in Type 2 
Diabetes Mellitus Patients. PBO, placebo; EMPA, empagliflozin; SoC, standard of care; CV, 
cardiovascular; MI, myocardial infarction; HHF, hospitalization for heart failure; MACE, major 
adverse cardiovascular events 
 
Figure 2: Box-and-Whisker plots of predicted event rates (per 1000 patient-years) for key 
macrovascular outcomes, by scenario and arm in the CANVAS Program Challenge. Event rates 
observed in the CANVAS Program are depicted by stars.  
CANVAS, the Canagliflozin Cardiovascular Assessment Study; PBO, placebo; CANA, 
canagliflozin; HR, hazard ratio; EMPA, empagliflozin; SoC, standard of care; CV, cardiovascular; MI, 
myocardial infarction; HHF, hospitalization for heart failure; MACE, major adverse cardiovascular 
event. 
 
